title: Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis.
abstract: Omega-3 fatty acids (O3FAs) are associated with lower cardiovascular disease (CVD) risk in adults. However, this association in patients with end-stage renal disease (ESRD) remains controversial prompting the need for investigation into the role of O3FAs on serum lipids and vascular inflammation markers. The present meta-analysis summarized the effects of O3FA supplementation on serum lipids and vascular inflammatory markers in patients with ESRD. PubMed, EmBase, and the Cochrane Library were searched to identify randomized controlled trials (RCTs) focused on serum lipids and vascular inflammation markers in patients with ESRD. Standard mean differences (SMD) were used to measure the effect of O3FA supplementation on serum lipids and vascular inflammatory markers. The final pooled analysis included 20 RCTs involving 1,461 patients with ESRD. The results indicated that O3FA supplementation reduced TG by 0.61, LDL by 0.35 and CRP by 0.56. However, O3FA had no significant effect on TC, HDL, albumin, hemoglobin, homocysteine, DBP, glucose, lipoprotein(a), and ferritin. O3FA supplementation is associated with lower several serum lipids and vascular inflammation markers in patients with ESRD.
authors.affiliation: Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Tianhua
authors.initials: T
authors.lastname: Xu
authors.affiliation: Department of Clinical Medicine, China Medical University, Shenyang 110001, China.
authors.forename: Yiting
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Sun
authors.affiliation: Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Li
authors.initials: L
authors.lastname: Yao
authors.affiliation: Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Li
authors.initials: L
authors.lastname: Sun
authors.affiliation: Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Linlin
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Jianfei
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Nephrology, The First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Lining
authors.initials: L
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D019587:Dietary Supplements; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D044967:Serum / Q000737:chemistry*; D016896:Treatment Outcome; D014657:Vasculitis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D015525:Fatty Acids, Omega-3; D008055:Lipids